BridGene Biosciences Secures $28 Million Series B+ to Advance TEAD Inhibitor and Expand IMTAC Platform

New updates have been reported about BridGene Biosciences.

BridGene Biosciences has raised $28 million in a Series B+ financing that materially extends its clinical and platform runway, positioning the company to advance its lead oncology asset and broaden its chemoproteomics-driven pipeline. The round was led by Bayland Capital with participation from GTJA Investment Group, Proxima Ventures, and existing backers Lapam Capital and Grains Valley Venture Capital. BridGene plans to deploy the capital primarily to move BGC-515, a covalent TEAD inhibitor for solid tumors, through ongoing clinical development toward Phase 2, a key value-inflection milestone for the company and its investors. The funding will also underwrite preparations for a second program expected to enter the clinic in 2027 and support additional preclinical programs in oncology and autoimmune disease, reinforcing BridGene’s strategy of targeting traditionally undruggable proteins.

Beyond the pipeline, the financing is intended to accelerate the expansion and external validation of BridGene’s proprietary IMTAC (Isobaric Mass-Tagged Affinity Characterization) chemoproteomic platform, which screens covalent small molecules across the live-cell proteome to identify new binding sites and drug candidates. CEO and co-founder Ping Cao, Ph.D., emphasized that the new capital provides the resources needed to advance BGC-515 through Phase 2 while simultaneously progressing follow-on assets and building strategic collaborations around IMTAC across oncology, immunology, and neurology. Lead investor Bayland Capital highlighted IMTAC as a differentiated discovery engine for small molecules against hard-to-drug targets and cited BridGene’s growing pipeline as a driver of potential long-term value in biopharma. For executives and stakeholders, this round reduces near-term financing risk, supports a multi-asset clinical strategy centered on BGC-515, and aims to position BridGene as a partner of choice for chemoproteomics-enabled drug discovery in high-value disease areas.